NCT07148141Active, not recruiting
Impact of Breast Cancer on Human Folliculogenesis
Fertility Preservation for Patients With Breast Cancer: Altered Response to Ovarian Stimulation and Loss of Cholesterol Homeostasis in Ovarian Follicles
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
Advances in cancer diagnosis and treatments have improved the 5-year survival rate for patients over the last decade. Nevertheless, cancer treatments frequently alter patient's fertility, thus compromising their ability to conceive a child after remission. Consequently, it is recommended to propose fertility preservation to patients before cancer therapy. The reference technique for preserving women's fertility the vitrification of mature oocytes after hormonal stimulation. In the context of cancer, different studies have shown that ovarian response to stimulation seems to be altered compared to healthy context, with a reduced number of mature oocytes collected, and altered oocyte quality, thus reducing the number of oocytes capable of producing a viable embryo. Hence, cancer seems to exert a deleterious impact on women's fertility. Nevertheless, the mechanisms by which the cancer may impair the ovarian functions are poorly understood. This innovative project aims to study the impact of breast cancer itself (the most frequent cancer in reproductive-aged women) on ovarian functions, and more precisely on the cholesterol biosynthesis pathway. Indeed, cholesterol homeostasis is essential for oocyte maturation and fertilization. The objectives of this study are i) to evaluate the impact of breast cancer on ovarian reserve and response to hormonal stimulation according to the molecular subtypes of breast cancer and ii) to evaluate the impact of breast cancer on ovarian cholesterol homeostasis in granulosa cells and follicular fluids. This original approach will improve the understanding of the mechanisms underlying the impact of breast cancer on ovarian functions, and will have a strong clinical impact by helping to optimize fertility preservation strategies based on tumour molecular subtypes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 19 Aug 2025
- Start date
- 11 Jan 2019
- Primary completion date
- 2 May 2025
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Ovarian cancer
- NCT number
- NCT07148141
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 11 Jan 2019 to the primary completion date, 2 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any cancer treatments prior fertility preservation (tumour resection, chemotherapy, radiotherapy)
- Previous hormonal stimulation cycle of less than six months
Other illness
- Endocrine disease
Age
- Women below 18 years old and above 38 years old
Other
- Endometriosis
Who the study is looking for
- Women above 18 years old and below 38 years old
- First hormonal stimulation cycle
- No dysovulation
- No cancer treatments prior fertility preservation (tumour resection, chemotherapy, radiotherapy)
- Women capable of giving written informed consent to participate in the research study
- Affiliated to social welfare service
Age in the registry: 18 years to 38 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.